Japan drug firms seek new growth outlets: companies shift plans in bid to tap product pipelines

Article Abstract:

Because of impending drug patent expirations and subsequent revenue losses, Japanese pharmaceutical companies seek to grow through reorganization, corporate acquisitions, and investments on new product development. Article discusses Japanese drug companies's sales, cost control, strategic planning, and international competitiveness.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code:

Sales of key drugs lift net at Astellas, Eisai

Article Abstract:

Fiscal third-quarter net profits for Japanese pharmaceutical firms Eisai Company Ltd. and Astellas Pharma Inc. rose on strong sales. Net profit for Eisai rose 3.5% to 24.16 bil yen, with an increase in sales of 8.5%. Net profit for Astellas rose 52% to reach 161.24 bil yen, with sales increasing by 8.9%.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code:

Big drug makers in Japan report mixed results

Article Abstract:

First-quarter net profits for Japanese pharmaceutical companies showed both increases and losses. While Astellas Pharma Inc. had a 27% rise, Daiichi Sankyo Co. posted a 10% loss, and Eisai Company Ltd. reached a record net profit.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code: